Inositol versus placebo aumentation of serotonin reuptake inhibitor in the treatment of obsessive-compulsive disorder: A double-blind cross-over study

Mendel Fux; Jonathan Benjamin; R. H. Belmaker

doi:10.1017/S1461145799001546

Inositol versus placebo aumentation of serotonin reuptake inhibitor in the treatment of obsessive-compulsive disorder: A double-blind cross-over study

Mendel Fux, Jonathan Benjamin, R. H. Belmaker

Medical School for International Health

Research output: Contribution to journal › Article › peer-review

72 Scopus citations

Abstract

Current serotonin reuptake inhibitor (SRI) treatments for obsessive-compulsive disorder (OCD) provide only partial benefit. A previous study suggested that inositol alone is efficacious in OCD. Ten DSM-IV OCD patients completed a study of 18 g inositol or placebo for 6 wk each in addition to ongoing SRI treatment in a double-blind randomized cross-over design. Weekly assessments included the Yale-Brown Obsessive-Compulsive Scale (YBOCS) and Hamilton Depression and Anxiety scales. No significant difference was found between the two treatment phases.

Original language	English
Pages (from-to)	193-195
Number of pages	3
Journal	International Journal of Neuropsychopharmacology
Volume	2
Issue number	3
DOIs	https://doi.org/10.1017/S1461145799001546
State	Published - 1 Jan 1999

Keywords

Augmentation
Inositol
Obsessive-compulsive disorder
Serotonin reuptake inhibitors.

ASJC Scopus subject areas

Pharmacology
Psychiatry and Mental health
Pharmacology (medical)

Access to Document

10.1017/S1461145799001546

Cite this

@article{42368792412c42fd91ead6657628e260,

title = "Inositol versus placebo aumentation of serotonin reuptake inhibitor in the treatment of obsessive-compulsive disorder: A double-blind cross-over study",

abstract = "Current serotonin reuptake inhibitor (SRI) treatments for obsessive-compulsive disorder (OCD) provide only partial benefit. A previous study suggested that inositol alone is efficacious in OCD. Ten DSM-IV OCD patients completed a study of 18 g inositol or placebo for 6 wk each in addition to ongoing SRI treatment in a double-blind randomized cross-over design. Weekly assessments included the Yale-Brown Obsessive-Compulsive Scale (YBOCS) and Hamilton Depression and Anxiety scales. No significant difference was found between the two treatment phases.",

keywords = "Augmentation, Inositol, Obsessive-compulsive disorder, Serotonin reuptake inhibitors.",

author = "Mendel Fux and Jonathan Benjamin and Belmaker, {R. H.}",

year = "1999",

month = jan,

day = "1",

doi = "10.1017/S1461145799001546",

language = "English",

volume = "2",

pages = "193--195",

journal = "International Journal of Neuropsychopharmacology",

issn = "1461-1457",

publisher = "Oxford University Press",

number = "3",

}

TY - JOUR

T1 - Inositol versus placebo aumentation of serotonin reuptake inhibitor in the treatment of obsessive-compulsive disorder

T2 - A double-blind cross-over study

AU - Fux, Mendel

AU - Benjamin, Jonathan

AU - Belmaker, R. H.

PY - 1999/1/1

Y1 - 1999/1/1

N2 - Current serotonin reuptake inhibitor (SRI) treatments for obsessive-compulsive disorder (OCD) provide only partial benefit. A previous study suggested that inositol alone is efficacious in OCD. Ten DSM-IV OCD patients completed a study of 18 g inositol or placebo for 6 wk each in addition to ongoing SRI treatment in a double-blind randomized cross-over design. Weekly assessments included the Yale-Brown Obsessive-Compulsive Scale (YBOCS) and Hamilton Depression and Anxiety scales. No significant difference was found between the two treatment phases.

AB - Current serotonin reuptake inhibitor (SRI) treatments for obsessive-compulsive disorder (OCD) provide only partial benefit. A previous study suggested that inositol alone is efficacious in OCD. Ten DSM-IV OCD patients completed a study of 18 g inositol or placebo for 6 wk each in addition to ongoing SRI treatment in a double-blind randomized cross-over design. Weekly assessments included the Yale-Brown Obsessive-Compulsive Scale (YBOCS) and Hamilton Depression and Anxiety scales. No significant difference was found between the two treatment phases.

KW - Augmentation

KW - Inositol

KW - Obsessive-compulsive disorder

KW - Serotonin reuptake inhibitors.

UR - http://www.scopus.com/inward/record.url?scp=0000860144&partnerID=8YFLogxK

U2 - 10.1017/S1461145799001546

DO - 10.1017/S1461145799001546

M3 - Article

AN - SCOPUS:0000860144

SN - 1461-1457

VL - 2

SP - 193

EP - 195

JO - International Journal of Neuropsychopharmacology

JF - International Journal of Neuropsychopharmacology

IS - 3

ER -

Inositol versus placebo aumentation of serotonin reuptake inhibitor in the treatment of obsessive-compulsive disorder: A double-blind cross-over study

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this